This website is for UK Healthcare Professionals.

Product information 

Lenalidomide Accord presentations

Tablet images not to scale

Presentations

Each presentation is available in packs of 21 hard capsules

size 5

2.5mg

11.0 mm to 11.8 mm

size 5

5mg

11.0 mm to 11.8 mm

size 4

7.5mg

14.0 mm to 14.8 mm

size 3

10mg

15.4 mm to 16.2 mm

Shelf life

3 years

15-mg

size 2

15mg

17.4 mm to 18.2 mm

size 1

20mg

19.0 mm to 19.8 mm

size 0

25mg

21.0 mm to 21.8 mm

Packaging

Cross-perforated unit-dose blisters

  • All relevant information is contained in each blister socket: product name, active substance, pharmaceutical form, dose, lot and expiry date.

Colour strength differentiated blisters

  • The strength is highlighted with a colour which matches dose colour helping to mitigate dispensing errors by clearly differentiating each dose.

Data Matrix included on the blister

  • Assists product traceability and dispensation.

Launched January 2022

Lenalidomide Accord hard capsules

Offering the same range of strengths and for the same indications as Revlimid®*:4, 5
  • Multiple myeloma
  • Myelodysplastic syndrome
  • Mantle cell lymphoma
  • Follicular lymphoma

Differentiated packaging to aid dispensing

*Please refer to the prescribing information for the full list of indications
Launched February 2021

Thalidomide hard capsules

  • Offering the same strength and indication as thalidomide BMS*1,2
  • Multiple myeloma
  • The only generic thalidomide3
*Please refer to the prescribing information for the full list of indications

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Accord-UK Ltd on 01271 385257 or email [email protected].

References

  1. Accord-UK Ltd. Thalidomide Summary of Product Characteristics
  2. Bristol Myers Squibb Pharmaceuticals Ltd. Thalidomide BMS Summary of Product Characteristics
  3. British National Formulary. Thalidomide. Available at: https://bnf.nice.org.uk/drugs/thalidomide-specialist-drug/medicinal-forms/ (Accessed April 2024)
  4. Accord Healthcare Ltd. Lenalidomide Accord Summary of Product Characteristics
  5. Bristol Myers Squibb Pharmaceuticals Ltd. Revlimid® Summary of Product Characteristics

UK-03777 April 2024

UK-03777 April 2024

Copyright 2024 All rights reserved.

Please select

For UK Healthcare Professionals

If you are a UK healthcare professional and would like more information on lenalidomide or thalidomide from Accord, please click here
Continue to website

Report Adverse Events

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to Accord-UK Ltd:

Tel: 01271 385257
Email: [email protected]

For the UK Public

For more information on lenalidomide or thalidomide from Accord, please click below .

Click here to view the Information for Patients Taking Lenalidomide leaflet
Click here to view the Information for Patients Taking Thalidomide leaflet

Site intended for a UK audience only. UK-03777 April 2024